IL6 and melanoma: Depletion of macrophages in vivo model of melanoma reduces the systemic level of IL6 and upregulates anti-tumor Th1 response, suggesting that the narrow therapeutic window of PD1–PDL1 blockade can be overcome by inhibition of IL6 (104).